Clinical Trial Update: Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

View source ↗

Summary

Expanded access program update for aztreonam lysine inhalation (Cayston) in Canadian cystic fibrosis patients, noting marketing approval status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pseudomonas Aeruginosa Infection

Drugs mentioned

• Cayston (aztreonam lysine)

Snippet

Sponsor: Gilead Sciences | Conditions: Cystic Fibrosis, Pseudomonas Aeruginosa | Status: APPROVED_FOR_MARKETING